title: Epidemiology of Cervical Squamous Intraepithelial Lesions in HIV Infected Women in Kenya: a cross-Sectional Study.
abstract: Cervical cancer is the second most common cancer among women worldwide. Infection with the human immunodeficiency virus (HIV) and its related immunosuppression are associated with an increased risk of prevalent, incident, and persistent squamous intraepithelial lesions (SILs) of the cervix. The objective of the study was to describe the prevalence and predictors of high-risk HPV and cervical cancer to support the need for strengthening cervical cancer screening programs for HIV infected women in Kenya. A cross sectional study was conducted in a hospital in Central Kenya, Kiambu district. The study population constituted of HIV positive women attending the ART treatment clinic. A total of 715 HIV positive women initiated on Antiretroviral Therapy (ART) were enrolled in this study. About 359 (52.1%) were less than 40 years of age and 644 (90.3%) of the patients were widowed. About 642 (92.6%) of the HIV infected women were in follow-up period of ≥ 1 year. The outcome/prognosis of the patients undergoing ICC was 3 cured, 5 good and 4 poor respectively. In a multivariable ordinal logistic regression analysis showed that for a one-unit decrease of CD4, we expect 1.23 log odds of increasing the severity of cervical cancer (B = 1.23, P < 0.0 15), given that all of the other variables in the model are held constant. In conclusion screening of all HIV infected women, who are under HIV care and treatment, enrolling patients on HAART with higher CD4 counts is recommended to see the net effect of HAART response.
authors.forename: Peter
authors.initials: P
authors.lastname: Memiah
authors.forename: Violet
authors.initials: V
authors.lastname: Makokha
authors.forename: Wangeci
authors.initials: W
authors.lastname: Mbuthia
authors.forename: Grace Wanjiku
authors.initials: GW
authors.lastname: Kiiru
authors.forename: Solomon
authors.initials: S
authors.lastname: Agbor
authors.forename: Francesca
authors.initials: F
authors.lastname: Odhiambo
authors.forename: Sylvia
authors.initials: S
authors.lastname: Ojoo
authors.forename: Justice
authors.initials: J
authors.lastname: Mbizo
authors.forename: Samuel
authors.initials: S
authors.lastname: Muhula
authors.forename: Gabriel
authors.initials: G
authors.lastname: Mahasi
authors.forename: Sibhatu
authors.initials: S
authors.lastname: Biadgilign
mesh_terms: D000230:Adenocarcinoma / Q000453:epidemiology* / Q000473:pathology; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology* / Q000473:pathology; D060085:Coinfection; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D007630:Kenya / Q000453:epidemiology; D016015:Logistic Models; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000453:epidemiology*; D065310:Squamous Intraepithelial Lesions of the Cervix / Q000453:epidemiology* / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology* / Q000473:pathology; D055815:Young Adult
chemical_list: D019380:Anti-HIV Agents